BU-NOT-SET

CONTACT US
Relocating API supply to avoid over-reliance
  • Drug substance
Eyes
Insight
Modified release fixed dose combination product with two poorly soluble drug substances
  • Drug product
pellets
Case study
Patient centricity during drug development and commercialisation
  • Drug product
Eyes
Insight
10 considerations to kick-start your drug development journey
  • Drug product
Eyes
Insight
Guidance for start-ups on drug development
  • Drug product
Eyes
Insight
Drug development for start-ups
  • Drug product
  • Drug substance
Test tubes
White paper
Optimising environmental sustainability
  • Sustainability
Eyes
Insight
Adapting to deal with the COVID-19 pandemic
  • Industry trends
Eyes
Insight
On Drug Delivery – Sustainability Q&A
  • Sustainability
Eyes
Insight
Insight
  • Drug substance
Regulatory requirements for drug substances
Insight
  • Analytical chemistry
The QbD approach: Key advantages in clinical and commercial phases
Report
  • Sustainability
Sustainability report 2020
Poster
  • Drug substance
Recipharm and Oncopeptides: Successful collaboration in the development of melflufen, a peptidase-potentiated alkylating agent in clinical trials
Fact sheet
  • Analytical chemistry
Recipharm Analytical Solutions™
Fact sheet
  • Analytical chemistry
Impurity identification
Fact sheet
  • Analytical chemistry
Stability studies
Fact sheet
  • Analytical chemistry
Extractables & leachables testing
Insight
  • Industry trends
Pharmaceutical mergers and acquisitions: opportunities and drivers for CDMOs